A Phase 2 interventional study of Sorafenib and BIBF 1120 in Carcinoma, Hepatocellular, sponsored by Boehringer Ingelheim. Completed at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-10.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 273 studies in Carcinoma, Hepatocellular with a site in Taiwan — 46 open to participants now, 69 under way, 11 of them phase 3. Carcinoma, Hepatocellular · Taiwan.
Among the 273 studies in Carcinoma, Hepatocellular with a site in Taiwan, this one is the 94th largest by enrollment of the 224 interventional ones that give a count, is one of 19 that started in 2009, is one of 70 in phase 2, and was the 57th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.
Browse Carcinoma, Hepatocellular studies →46 of the 273 studies in Carcinoma, Hepatocellular with a site in Taiwan are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Taiwan, Australia, Georgia and 2 more countries
Ages 18+
CatalYm GmbH · Sites in Taiwan, United States, France and 4 more countries
Ages 18–100
Bristol-Myers Squibb · Sites in Taiwan, United States, Australia and 11 more countries
Ages 18+
Kaohsiung Medical University Chung-Ho Memorial Hospital · Sites in Taiwan
Ages 18–80
National Taiwan University Hospital · Sites in Taiwan
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
273 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 65 · Phase 2 107 · Phase 3 52 · Phase 4 13
First in 1997; this study’s year is marked. 19 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 134 is above the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 98 across the 224 interventional studies, 164 across the 47 observational. Of the 156 that completed or were terminated, 59 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
149 of 273 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 3 studies filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
15 of the studies in Carcinoma, Hepatocellular with a site in Taiwan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06109272Phase 3AbbVieA Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | 2027-01 |
| NCT05822752AbbVieStudy to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | 2026-11 |
| NCT05613621National Health Research Institutes, TaiwanDissection of the Molecular and Immunological Interaction in Patients With HCC of Viral and Non-viral Etiologies | 2026-12-31 |
| NCT05257590TaiRx, Inc.CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma | 2026-12-31 |
| NCT05331911Kaohsiung Medical University Chung-Ho Memorial HospitalImpact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 273 studies in Carcinoma, Hepatocellular with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the safety, appropriate dose, and efficacy of BIBF 1120 in liver cancer patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase I dose escalation and phase II using dose determined in phase I
Drug: BIBF 1120
Twice daily dosing in phase II
Drug: Sorafenib
Maximum Tolerated Dose in Phase I
The MTD was defined as the highest dose studied for which the incidence of DLTs was 0/3 or less than 2/6 patients during the first treatment course.
Time frame: 4 weeks
Time to Progression (TTP) in Phase II
TTP according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.0 criteria based on central independent review. TTP RECIST 1.0 was defined as the time from randomisation to disease progression according to RECIST 1.0.
Time frame: From randomization until data cut-off (28 Sep 2012); Up to 77 weeks
Time to Progression (TTP) in Phase II (Follow-up Analyses)
TTP according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.0 criteria based on central independent review. TTP RECIST 1.0 was defined as the time from randomisation to disease progression according to RECIST 1.0.
Time frame: From randomization until disease progression or data cut-off (16 Jul 2014); Up to 171 weeks
Incidence and Intensity of Adverse Events (AEs) Reported as the Number of Patients With AEs According to Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Throughout the Treatment Period.
Incidence and worst intensity (severity) of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0).
Time frame: AEs with an onset during therapy with study treatment or within 28 days after discontinuation of study treatment (up to 1066 days)
Incidence of Dose Limiting Toxicity in Phase I
Number of patients with dose limiting toxicity are presented
Time frame: 4 weeks
Objective Tumour Response by RECIST
Objective RECIST 1.0 tumour response was defined as Complete Response (CR) or Partial Response (PR) and was derived from the patient's best objective RECIST 1.0 response based on central independent review. 95% Confidence Interval presented below are computed by Clopper and Pearson method.
Time frame: From randomization until data cut-off (16 July 2014); Up to 171 weeks
Progression Free Survival (PFS)
PFS by RECIST 1.0 was defined as the duration from date of randomisation to date of progression or death, whichever occurred earlier, based on central independent review.
Time frame: From randomization until data cut-off (16 July 2014); Up to 171 weeks
Overall Survival
Overall survival was defined as the duration from date of randomisation to the date of death.
Time frame: From randomization until data cut-off (16 July 2014); Up to 171 weeks
AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of Nintedanib
AUC0-12,ss,norm (area under the plasma concentration-time curve between 0 and 12 hours at steady state, normalised values) of Nintedanib Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.
Time frame: Day1, Day15 and Day 16
AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of BIBF 1202 (Metabolite of Nintedanib)
AUC0-12,ss,norm (area under the plasma concentration-time curve between 0 and 12 hours at steady state, normalised values) of BIBF 1202 (metabolite of Nintedanib). Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.
Time frame: Day1, Day15 and Day 16
AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of BIBF 1202 Glucuronide (Metabolite of Nintedanib)
AUC0-12,ss,norm of BIBF 1202 glucuronide (Metabolite of Nintedanib): Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.
Time frame: Day1, Day15 and Day 16
Cmax,ss,Norm (Maximum Concentration of the Nintedanib in Plasma at Steady State, Normalised Values)
Cmax,ss,norm (maximum concentration of the Nintedanib in plasma at steady state, normalised values). Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.
Time frame: Day1, Day15 and Day 16
Cmax,ss,Norm (Maximum Concentration of the BIBF 1202 in Plasma at Steady State, Normalised Values)
Cmax,ss,norm (maximum concentration of the BIBF 1202 in plasma at steady state, normalised values). Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.
Time frame: Day1, Day15 and Day 16
Cmax,ss,Norm (Maximum Concentration of the BIBF 1202 Glucuronide in Plasma at Steady State, Normalised Values)
Cmax,ss,norm (maximum concentration of the BIBF 1202 glucuronide in plasma at steady state, normalised values). Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.
Time frame: Day1, Day15 and Day 16
fe0-12,ss (Fraction Excreted in Urine Between 0 and 12 Hours at Steady State) for Nintedanib
fe0-12,ss (fraction excreted in urine between 0 and 12 hours at steady state) for Nintedanib. The reported value corresponds to the percentage of administered dose.
Time frame: 0 to 4 hours (h), 4 to 12 h, and 12 to 24 h after nintedanib
The trial consisted of 2 Phases. Patients were stratified into 1 of 2 groups according to their aspartate aminotransferase (AST)/alanine aminotransferase (ALT) and Child-Pugh score at baseline.
| Milestone | Phase I Group I, 100 mg Nintedanib Bid | Phase I Group 1, 150 mg Nintedanib Bid | Phase I Group 1, 200 mg Nintedanib Bid | Phase I Group 2, 50 mg Nintedanib Bid | Phase I Group 2, 100 mg Nintedanib Bid | Phase I Group 2, 150 mg Nintedanib Bid | Phase I Group 2, 200 mg Nintedanib Bid | Phase II, 200 mg Nintedanib Bid | Phase II, 400 mg Sorafenib Bid |
|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 3 | 3 | 3 | 7 | 3 | 16 | 63 | 32 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Not completed | 4 | 3 | 3 | 3 | 7 | 3 | 15 | 62 | 32 |
| Withdrew: Progressive disease | 3 | 2 | 3 | 2 | 5 | 3 | 9 | 48 | 23 |
| Withdrew: Adverse event | 0 | 1 | 0 | 1 | 1 | 0 | 2 | 10 | 6 |
| Withdrew: Refused to continue taking trial med. | 1 | 0 | 0 | 0 | 1 | 0 | 4 | 4 | 2 |
| Withdrew: Reason other than those specified above | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
The MTD was defined as the highest dose studied for which the incidence of DLTs was 0/3 or less than 2/6 patients during the first treatment course.
| mg | Group 1 | Group 2 |
|---|---|---|
| Maximum Tolerated Dose in Phase I | 200 | 200 |
TTP according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.0 criteria based on central independent review. TTP RECIST 1.0 was defined as the time from randomisation to disease progression according to RECIST 1.0.
| months | Phase II, 200 mg Nintedanib Bid | Phase II, 400 mg Sorafenib Bid |
|---|---|---|
| Time to Progression (TTP) in Phase II | 2.73 (0.99 to 5.55) | 3.71 (1.77 to 7.36) |
TTP according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.0 criteria based on central independent review. TTP RECIST 1.0 was defined as the time from randomisation to disease progression according to RECIST 1.0.
| months | Phase II, 200 mg Nintedanib Bid | Phase II, 400 mg Sorafenib Bid |
|---|---|---|
| Time to Progression (TTP) in Phase II (Follow-up Analyses) | 2.76 (0.99 to 5.55) | 3.71 (1.77 to 7.36) |
Incidence and worst intensity (severity) of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0).
| participants | Phase I Group I, 100 mg Nintedanib Bid | Phase I Group 1, 150 mg Nintedanib Bid | Phase I Group 1, 200 mg Nintedanib Bid | Phase I Group 2, 50 mg Nintedanib Bid | Phase I Group 2, 100 mg Nintedanib Bid | Phase I Group 2, 150 mg Nintedanib Bid | Phase I Group 2, 200 mg Nintedanib Bid | Phase II, 200 mg Nintedanib Bid | Phase II, 400 mg Sorafenib Bid |
|---|---|---|---|---|---|---|---|---|---|
| Grade 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 12 | 1 |
| Grade 2 | 2 | 2 | 1 | 0 | 0 | 1 | 4 | 15 | 4 |
| Grade 3 | 2 | 1 | 1 | 1 | 3 | 2 | 5 | 17 | 18 |
| Grade 4 | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 8 | 5 |
| Grade 5 | 0 | 0 | 0 | 0 | 2 | 0 | 5 | 10 | 4 |
Number of patients with dose limiting toxicity are presented
| participants | Phase I Group 1, 100 mg Nintedanib Bid | Phase I Group 1, 150 mg Nintedanib Bid | Phase I Group 1, 200 mg Nintedanib Bid | Phase I Group 2, 50 mg Nintedanib Bid | Phase I Group 2, 100 mg Nintedanib Bid | Phase I Group 2, 150 mg Nintedanib Bid | Phase I Group 2, 200 mg Nintedanib Bid |
|---|---|---|---|---|---|---|---|
| Incidence of Dose Limiting Toxicity in Phase I | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Objective RECIST 1.0 tumour response was defined as Complete Response (CR) or Partial Response (PR) and was derived from the patient's best objective RECIST 1.0 response based on central independent review. 95% Confidence Interval presented below are computed by Clopper and Pearson method.
| percentage of participants | Phase II, 200 mg Nintedanib Bid | Phase II, 400 mg Sorafenib Bid |
|---|---|---|
| Objective Tumour Response by RECIST | 6.3 (1.8 to 15.5) | 3.1 (0.1 to 16.2) |
PFS by RECIST 1.0 was defined as the duration from date of randomisation to date of progression or death, whichever occurred earlier, based on central independent review.
| months | Phase II, 200 mg Nintedanib Bid | Phase II, 400 mg Sorafenib Bid |
|---|---|---|
| Progression Free Survival (PFS) | 2.66 (0.99 to 5.55) | 3.71 (1.77 to 7.36) |
Overall survival was defined as the duration from date of randomisation to the date of death.
| months | Phase II, 200 mg Nintedanib Bid | Phase II, 400 mg Sorafenib Bid |
|---|---|---|
| Overall Survival | 10.18 (5.19 to 16.85) | 10.71 (7.29 to 16.66) |
AUC0-12,ss,norm (area under the plasma concentration-time curve between 0 and 12 hours at steady state, normalised values) of Nintedanib Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.
| (ng*h/mL)/mg | Group 1 | Group 2 |
|---|---|---|
| AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of Nintedanib | 1.97 ± 97.1 | 3.82 ± 64.1 |
AUC0-12,ss,norm (area under the plasma concentration-time curve between 0 and 12 hours at steady state, normalised values) of BIBF 1202 (metabolite of Nintedanib). Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.
| (ng*h/mL)/mg | Group 1 | Group 2 |
|---|---|---|
| AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of BIBF 1202 (Metabolite of Nintedanib) | 3.50 ± 157 | 8.95 ± 114 |
AUC0-12,ss,norm of BIBF 1202 glucuronide (Metabolite of Nintedanib): Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.
| (ng*h/mL)/mg | Group 1 | Group 2 |
|---|---|---|
| AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of BIBF 1202 Glucuronide (Metabolite of Nintedanib) | 16.9 ± 144 | 45.0 ± 124 |
Cmax,ss,norm (maximum concentration of the Nintedanib in plasma at steady state, normalised values). Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.
| (ng/mL)/mg | Group 1 | Group 2 |
|---|---|---|
| Cmax,ss,Norm (Maximum Concentration of the Nintedanib in Plasma at Steady State, Normalised Values) | 0.348 ± 98.8 | 0.630 ± 68.9 |
Cmax,ss,norm (maximum concentration of the BIBF 1202 in plasma at steady state, normalised values). Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.
| (ng/mL)/mg | Group 1 | Group 2 |
|---|---|---|
| Cmax,ss,Norm (Maximum Concentration of the BIBF 1202 in Plasma at Steady State, Normalised Values) | 0.519 ± 148 | 1.01 ± 118 |
Cmax,ss,norm (maximum concentration of the BIBF 1202 glucuronide in plasma at steady state, normalised values). Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.
| (ng/mL)/mg | Group 1 | Group 2 |
|---|---|---|
| Cmax,ss,Norm (Maximum Concentration of the BIBF 1202 Glucuronide in Plasma at Steady State, Normalised Values) | 1.56 ± 139 | 3.48 ± 139 |
fe0-12,ss (fraction excreted in urine between 0 and 12 hours at steady state) for Nintedanib. The reported value corresponds to the percentage of administered dose.
| percentage | Group 1 | Group 2 |
|---|---|---|
| fe0-12,ss (Fraction Excreted in Urine Between 0 and 12 Hours at Steady State) for Nintedanib | 0.227 ± 94.6 | 0.286 ± 46.0 |
Collected over AEs with an onset during therapy with study treatment or within 28 days after discontinuation of study treatment (up to 1066 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase I Group I Nintedanib, 100 mg Bid | — | 2/4 (50%) | 4/4 (100%) |
| Phase I Group I Nintedanib, 150 mg Bid | — | 1/3 (33.3%) | 3/3 (100%) |
| Phase I Group I Nintedanib, 200 mg Bid | — | 0/3 (0%) | 3/3 (100%) |
| Phase I Group II Nintedanib, 50 mg Bid | — | 3/3 (100%) | 3/3 (100%) |
| Phase I Group II Nintedanib, 100 mg Bid | — | 4/7 (57.1%) | 7/7 (100%) |
| Phase I Group II Nintedanib, 150 mg Bid | — | 1/3 (33.3%) | 3/3 (100%) |
| Phase I Group II Nintedanib, 200 mg Bid | — | 10/16 (62.5%) | 16/16 (100%) |
| Phase II Nintedanib, 200 mg Bid | — | 29/63 (46%) | 61/63 (96.8%) |
| Phase II Sorafenib, 400 mg Bid | — | 18/32 (56.3%) | 32/32 (100%) |
| Event | Phase I Group I Nintedanib, 100 mg Bid | Phase I Group I Nintedanib, 150 mg Bid | Phase I Group I Nintedanib, 200 mg Bid | Phase I Group II Nintedanib, 50 mg Bid | Phase I Group II Nintedanib, 100 mg Bid | Phase I Group II Nintedanib, 150 mg Bid | Phase I Group II Nintedanib, 200 mg Bid | Phase II Nintedanib, 200 mg Bid | Phase II Sorafenib, 400 mg Bid |
|---|---|---|---|---|---|---|---|---|---|
| Haemorrhagic anaemiaBlood and lymphatic system disorders | 0/4 | 0/3 | 0/3 | 1/3 | 0/7 | 0/3 | 0/16 | 0/63 | 0/32 |
| Abdominal distensionGastrointestinal disorders | 0/4 | 1/3 | 0/3 | 0/3 | 1/7 | 0/3 | 0/16 | 0/63 | 1/32 |
| Abdominal painGastrointestinal disorders | 0/4 | 0/3 | 0/3 | 1/3 | 0/7 | 0/3 | 1/16 | 1/63 | 1/32 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/4 | 0/3 | 0/3 | 1/3 | 0/7 | 0/3 | 0/16 | 1/63 | 0/32 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/4 | 0/3 | 0/3 | 1/3 | 0/7 | 1/3 | 0/16 | 3/63 | 1/32 |
| HepatitisHepatobiliary disorders | 0/4 | 0/3 | 0/3 | 1/3 | 0/7 | 0/3 | 0/16 | 0/63 | 0/32 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/4 | 0/3 | 0/3 | 1/3 | 0/7 | 0/3 | 0/16 | 0/63 | 0/32 |
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/4 | 0/3 | 0/3 | 1/3 | 2/7 | 0/3 | 1/16 | 0/63 | 0/32 |
| VomitingGastrointestinal disorders | 1/4 | 0/3 | 0/3 | 0/3 | 1/7 | 0/3 | 1/16 | 0/63 | 0/32 |
| HeadacheNervous system disorders | 1/4 | 0/3 | 0/3 | 0/3 | 0/7 | 0/3 | 0/16 | 0/63 | 0/32 |
| Event | Phase I Group I Nintedanib, 100 mg Bid | Phase I Group I Nintedanib, 150 mg Bid | Phase I Group I Nintedanib, 200 mg Bid | Phase I Group II Nintedanib, 50 mg Bid | Phase I Group II Nintedanib, 100 mg Bid | Phase I Group II Nintedanib, 150 mg Bid | Phase I Group II Nintedanib, 200 mg Bid | Phase II Nintedanib, 200 mg Bid | Phase II Sorafenib, 400 mg Bid |
|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/4 | 1/3 | 0/3 | 2/3 | 5/7 | 3/3 | 6/16 | 28/63 | 18/32 |
| Decreased appetiteMetabolism and nutrition disorders | 1/4 | 1/3 | 0/3 | 3/3 | 2/7 | 1/3 | 8/16 | 25/63 | 8/32 |
| HyponatraemiaMetabolism and nutrition disorders | 0/4 | 0/3 | 0/3 | 3/3 | 1/7 | 0/3 | 0/16 | 2/63 | 2/32 |
| InsomniaPsychiatric disorders | 0/4 | 0/3 | 0/3 | 1/3 | 2/7 | 3/3 | 0/16 | 9/63 | 4/32 |
| AnaemiaBlood and lymphatic system disorders | 1/4 | 0/3 | 1/3 | 2/3 | 1/7 | 1/3 | 3/16 | 12/63 | 5/32 |
| NeutropeniaBlood and lymphatic system disorders | 0/4 | 0/3 | 0/3 | 0/3 | 0/7 | 2/3 | 1/16 | 4/63 | 1/32 |
| Abdominal distensionGastrointestinal disorders | 1/4 | 1/3 | 2/3 | 2/3 | 3/7 | 0/3 | 3/16 | 18/63 | 3/32 |
| Abdominal painGastrointestinal disorders | 0/4 | 2/3 | 2/3 | 2/3 | 1/7 | 1/3 | 2/16 | 11/63 | 10/32 |
| NauseaGastrointestinal disorders | 2/4 | 1/3 | 1/3 | 2/3 | 2/7 | 2/3 | 7/16 | 19/63 | 4/32 |
| Mucosal inflammationGeneral disorders | 0/4 | 2/3 | 0/3 | 0/3 | 0/7 | 0/3 | 2/16 | 2/63 | 2/32 |
Treated set (TS): Treated set included all patients who received at least one dose of trial medication
| Age, Continuous(years) | Phase I Group I, 100 mg Nintedanib Bid | Phase I Group 1, 150 mg Nintedanib Bid | Phase I Group 1, 200 mg Nintedanib Bid | Phase I Group 2, 50 mg Nintedanib Bid | Phase I Group 2, 100 mg Nintedanib Bid | Phase I Group 2, 150 mg Nintedanib Bid | Phase I Group 2, 200 mg Nintedanib Bid | Phase II, 200 mg Nintedanib Bid | Phase II, 400 mg Sorafenib Bid | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 44.5 ± 14.5 | 55.7 ± 4.2 | 47.7 ± 6.8 | 64.3 ± 15.3 | 62.3 ± 11.1 | 68.7 ± 10.1 | 56.1 ± 11.7 | 58.2 ± 12.6 | 61.2 ± 11.5 | 58.6 ± 12.3 |
| Sex: Female, Male(Participants) | Phase I Group I, 100 mg Nintedanib Bid | Phase I Group 1, 150 mg Nintedanib Bid | Phase I Group 1, 200 mg Nintedanib Bid | Phase I Group 2, 50 mg Nintedanib Bid | Phase I Group 2, 100 mg Nintedanib Bid | Phase I Group 2, 150 mg Nintedanib Bid | Phase I Group 2, 200 mg Nintedanib Bid | Phase II, 200 mg Nintedanib Bid | Phase II, 400 mg Sorafenib Bid | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 6 | 6 | 16 |
| Male | 4 | 3 | 3 | 3 | 7 | 2 | 13 | 57 | 26 | 118 |
The record gives a start of Oct 2009, a primary completion of Jul 2014 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib